Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Desalex Most Promoted for GPs in April amid Pollen Season: Anterio
June 20, 2018
- PII Data Suggest Acucela’s Emixustat Improves Macular Edema
June 20, 2018
- Enbrel 25 mg Pen Now Available: Pfizer/Takeda
June 19, 2018
- Quizartinib Cuts Risk of Death by 24% for AML: Daiichi Sankyo
June 19, 2018
- Nichi-Iko to Roll Out Enbrel Biosimilar under License Deal with Lupin
June 19, 2018
- Onychomycosis Treatment Efinaconazole Approved in Taiwan: Kaken, Mitsubishi Tanabe
June 18, 2018
- CSL Behring Japan Chief Eyes Double-Digit Growth for Next Few Years
June 18, 2018
- Shionogi Bags Some Asian Rights for Sage’s Depression Drug
June 15, 2018
- Authorized Generics for Aimix, Cravit IV Bag Hit Shelves; Takepron Out in September
June 15, 2018
- Velcade Gx Skips Listing, Teva Takeda Says Not Ready for Launch
June 15, 2018
- Eisai Enters Agreement with 6 Institutions for Nucleic Acid Drug Discovery Research; Project Selected for CiCLE Program
June 14, 2018
- Univ. of Tokyo, Fujitsu, Kowa Discover Novel Small Molecule Compounds Using IT-Based Drug Discovery
June 14, 2018
- US FDA Accepts NDA for Sunovion’s Parkinson’s Disease Treatment
June 14, 2018
- Eisai to Launch New US Research Center for Innovative Drug Discovery in Dementia Field
June 14, 2018
- Mochida Licenses EPA Technologies to Amarin
June 13, 2018
- EA Pharma Licenses SHPT Treatment to China Firm
June 13, 2018
- Angry Shareholders Say Don’t Make Takeda a Debt-Saddled Company
June 12, 2018
- Ethical Drug Sales Jump 7.6% in April on Price Revision: Crecon
June 12, 2018
- Parkinson’s Drug Azilect Now Available in Japan: Takeda
June 12, 2018
- Vortioxetine Showed Positive Results in Japan PIII with MDD Patients: Takeda/Lundbeck
June 12, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…